Key Highlights:

• CSL continues expanding its global plasma collection network and manufacturing capacity.

• Research and development remain central to the company's long-term strategy.

• Seqirus continues strengthening CSL's global vaccines business.

• Product innovation and pipeline development support future growth opportunities.

Healthcare innovation continues driving advances in biotechnology, specialty medicines and vaccine development as demand for complex therapies grows worldwide. CSL Ltd (ASX: CSL) continues strengthening its position as one of the world's leading biotechnology companies through investment in research, manufacturing and global commercial operations.

With operations spanning more than 100 countries, CSL continues expanding its plasma collection network, advancing new therapies and investing in manufacturing infrastructure to support growing global demand. Its diversified healthcare portfolio provides exposure across plasma-derived medicines, vaccines and innovative biotherapies.

Plasma Business Remains the Foundation

CSL Behring continues representing the company's largest business division.

The business develops and manufactures plasma-derived therapies used to treat patients with rare and serious diseases, including immune deficiencies, bleeding disorders and neurological conditions.

To support growing global demand, CSL continues expanding its plasma collection network while investing in processing capacity and manufacturing efficiency.

Maintaining a reliable plasma supply remains essential for supporting future product availability and long-term growth.

Research and Development Continue Driving Innovation

Innovation remains one of CSL's biggest competitive strengths.

The company continues investing billions of dollars in research and development to advance therapies across immunology, haematology, cardiovascular disease, respiratory medicine and rare diseases.

Clinical development programmes continue evaluating new treatment options while expanding the potential use of existing therapies.

Maintaining a diversified development pipeline remains central to the company's long-term growth strategy.

Seqirus Strengthens the Vaccines Business

CSL's Seqirus division remains one of the world's largest influenza vaccine businesses.

The company continues supplying seasonal influenza vaccines while investing in advanced manufacturing technologies and next-generation vaccine development.

Growing awareness of infectious diseases and ongoing investment in public health programmes continue supporting long-term demand for vaccine products.

Seqirus provides additional revenue diversification alongside CSL's plasma therapies.

Manufacturing Investment Supports Future Growth

Manufacturing capacity continues playing a critical role in CSL's long-term strategy.

The company has continued investing in new production facilities, plasma fractionation capability and advanced manufacturing technologies to improve efficiency and support future product demand.

These investments are expected to strengthen supply reliability while supporting commercialisation of pipeline products over the coming years.

Operational excellence remains an important priority across CSL's global manufacturing network.

Global Expansion Continues

CSL continues generating revenue from major healthcare markets across North America, Europe, Asia-Pacific and Latin America.

Its broad international presence provides access to diversified healthcare systems while reducing reliance on any single geographic region.

The company also continues strengthening relationships with hospitals, healthcare providers and governments through its global commercial infrastructure.

International diversification remains an important contributor to long-term business resilience.

Industry Outlook

Demand for specialty medicines, plasma therapies and vaccines is expected to continue growing as ageing populations, greater disease awareness and advances in medical science increase treatment availability.

Biotechnology companies with established manufacturing capabilities, global distribution networks and active research pipelines may remain well positioned to benefit from these long-term healthcare trends.

Innovation continues to be a major competitive differentiator across the global biotechnology sector.

Key Catalysts Investors May Monitor

• Plasma collection growth.

• Clinical trial and pipeline updates.

• Expansion of manufacturing capacity.

• Seqirus vaccine performance.

• Regulatory approvals.

• Annual financial performance.

Key Risks and Uncertainties

Like other biotechnology companies, CSL remains exposed to regulatory requirements, clinical development risks and manufacturing challenges.

Additional risks include changes in healthcare reimbursement, plasma collection volumes, foreign exchange movements and increasing competition across specialty medicines.

Future growth will also depend on successful product development and commercial execution.

Balanced Outlook

CSL continues executing a long-term strategy built around scientific innovation, manufacturing excellence and global healthcare leadership. Ongoing investment in plasma collection, research and development, vaccine production and commercial expansion positions the company to address growing demand for specialty medicines worldwide. As healthcare needs continue evolving, investors are expected to monitor pipeline progress, manufacturing expansion and commercial performance as key indicators of CSL's long-term growth trajectory.